4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.

Aktis Oncology develops precision radiopharmaceuticals that utilize targeted alpha-emitting particles to treat solid tumors in cancers with limited treatment options. Their technology aims to enhance the efficacy of cancer therapies by delivering localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.

The startup develops radar sensing technology that provides high-resolution imaging and real-time object detection for the automotive industry. This technology enhances vehicle safety and passenger comfort by improving situational awareness and reducing the risk of accidents.

Baropharm is an e-commerce platform that centralizes the ordering and return management of pharmaceutical products from wholesalers and manufacturers, streamlining pharmacy operations. The platform provides data analytics and membership benefits to enhance inventory management and operational efficiency for pharmacies.

Casma Therapeutics utilizes its PHLYT™ platform to enhance autophagic degradation of damaged cellular components, targeting diseases that existing therapies cannot effectively address. By reprogramming the natural cellular process of autophagy, the company aims to improve patient outcomes in conditions resistant to current drug treatments.

Cyrus Therapeutics develops small molecule drugs targeting previously undruggable proteins to treat chronic diseases. By utilizing advanced drug discovery techniques, the company aims to create effective therapies that address significant unmet medical needs.

Deeping Source utilizes patented video anonymization technology to transform CCTV footage into actionable insights for retail environments, enabling the collection of pre-purchase data without privacy violations. Their analytics platform provides real-time metrics on customer behavior, enhancing store efficiency and driving revenue growth through data-driven decision-making.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

Hummingbird Bioscience develops next-generation antibody-drug conjugates (ADCs) using proprietary linker-payload technologies to target cancer cells with high specificity. Their approach aims to provide effective treatment options for patients who do not respond to existing therapies, enhancing the potential for durable clinical responses.

The startup has developed an artificial intelligence platform that integrates machine learning, target discovery, and toxicity prediction to enhance drug research and development. This technology enables healthcare professionals to identify and create treatments for fibrosis, immune, and inflammatory diseases, ultimately improving patient outcomes.

Lunit develops AI-powered medical imaging solutions that enhance early-stage cancer detection and predict treatment responses for immunotherapy. By leveraging advanced algorithms, Lunit's technology increases the accuracy of cancer screenings and improves patient outcomes across over 3,800 healthcare sites in more than 50 countries.

Mars Auto provides an autonomous trucking platform that learns driving policies from sensor data collected on real freight fleets, using an end‑to‑end neural model that fuses 3‑D perception and planning without HD maps. The system is optimized for heavy‑duty trucks, delivering fuel‑efficient operation and safe braking on loaded vehicles for warehouse‑to‑warehouse routes. It includes a cloud‑based fleet management console for remote monitoring and continuous data‑driven improvement.

Mathpresso’s QANDA app is an AI‑powered platform that lets students capture math problems with their phone camera and receive instant, step‑by‑step solutions in multiple languages. It combines OCR and large language models to generate detailed explanations, recommend related practice items, and provide a searchable knowledge base, helping K‑12 and university learners get on‑demand math assistance anytime, anywhere.

Medipixel develops the MPXA, a software as a medical device that utilizes deep learning algorithms to perform real-time quantitative analysis of cardiovascular conditions during catheterization procedures. This technology enables intervention surgeons to receive accurate diagnostic insights in an average of 1.8 seconds, enhancing decision-making and improving patient outcomes.

Moloco provides programmatic advertising solutions that utilize machine learning algorithms to enhance client acquisition, retention, and monetization strategies. By optimizing ad placements and targeting, Moloco helps businesses improve their return on investment in digital marketing campaigns.

The startup specializes in molecular diagnostics by developing biomarkers through bioinformatics technology to enable precise disease risk analysis and targeted drug development. This approach enhances the accuracy of disease diagnosis for healthcare professionals, facilitating personalized treatment strategies.

Pharos iBio Co. utilizes its AI-driven Chemiverse® platform to develop targeted therapies for rare and intractable diseases by analyzing protein structures and leveraging big data. The company aims to provide effective treatment options for patients suffering from conditions that currently lack viable solutions.

Pinot Bio develops next-generation antibody-drug conjugates (ADCs) and targeted therapies, including the PINOT-ADC™ platform and the DNMT1 inhibitor NTX-301, to enhance the efficacy and safety of cancer treatments. The company addresses the limitations of existing cancer therapies by providing more effective and less toxic options for patients with solid tumors and hematological malignancies.

Rebellions develops AI accelerators that utilize HBM3e chiplet architecture and 5nm System-on-Chip technology to enhance energy efficiency and computational performance for deep learning applications. The company addresses the need for scalable and efficient AI inference solutions in the rapidly growing generative AI market.

S2W offers an AI-driven Cybercrime Intelligence Platform, XARVIS, that analyzes data from covert channels such as the Dark Web and Telegram to provide actionable insights for national security and public safety. The platform addresses the challenge of detecting and mitigating cyber threats by delivering real-time intelligence on emerging risks and vulnerabilities.

Saige Research develops AI-driven machine vision solutions for industrial inspection and quality control, utilizing deep learning algorithms to automate defect detection and real-time process monitoring. Their technology enhances product quality and workplace safety by identifying anomalies and potential hazards in manufacturing environments.

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

Ubix Therapeutics develops targeted anti-cancer drugs using proprietary drug delivery systems that enhance the efficacy of existing therapies. The company focuses on improving patient outcomes by increasing the precision of treatment while minimizing side effects associated with traditional cancer therapies.